



ASX Announcement | Friday, 8 November 2019

Update on Voluntary Suspension

Creso Pharma Limited (ASX:CPH) (“Creso Pharma” or “the Company”) refers to its request for a voluntary suspension of all quoted securities of the Company, dated 5 November 2019.

The Company had intended to today release an announcement regarding the proposed acquisition of the Company by PharmaCielo Limited by way of schemes of arrangement pursuant to the Scheme Implementation Agreement announced to ASX on 7 June 2019. The Company notes however that it is not in a position to release an announcement to the ASX at this time, and accordingly the Company’s securities will remain in voluntary suspension until the release of the aforementioned announcement, which is expected to be no later than Friday, 15 November 2019.

In light of the above, the Company currently anticipates that the Scheme Meetings that were scheduled to be held on Monday, 11 November 2019 will be adjourned.

Ends.

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 419 815 386

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.